DPP3

EQS-News: AdrenoMed Receives FDA Fast Track Designation for Enibarcimab for Treatment of Septic Shock

Retrieved on: 
Wednesday, April 10, 2024
Sepsis, Communication, Patient, Public, Fast Track, Adrenomedullin, Biomarker, Accelerated approval (FDA), Mortality, Septic shock, Death, DPP3, Septic, Medicine, Priority review, Organ dysfunction, Intensive care medicine, CMO, Collection, FDA, Infection, RCI, Food, Pharmaceutical industry

AdrenoMed is now preparing a confirmatory Phase IIb/III clinical trial to confirm the reduced septic shock mortality under enibarcimab treatment employing a precision medicine approach.

Key Points: 
  • AdrenoMed is now preparing a confirmatory Phase IIb/III clinical trial to confirm the reduced septic shock mortality under enibarcimab treatment employing a precision medicine approach.
  • AdrenoMed’s CEO Dr. Richard Jones commented: “We are very pleased that enibarcimab has received Fast Track designation from the FDA, recognizing its potential as an innovative biomarker-guided treatment against septic shock to fill the unmet medical need in this very serious condition with a high death toll.
  • With a mortality rate of 20-30% for sepsis [1] and 30%-50% for septic shock in developed countries, [2] sepsis represents an enormous public health burden and is responsible for almost 20% of all deaths worldwide.
  • Dr. Stephan Witte, CMO of AdrenoMed, said: “We are very confident that the use of enibarcimab in combination with two biomarkers, Adrenomedullin (bio-ADM) and circulating dipeptidyl peptidase 3 (cDPP3), holds the promise to become the first effective targeted treatment against septic shock.

EQS-News: Adrenomed presents new findings on its precision medicine treatment for septic shock with enibarcimab during Weimar Sepsis Update

Retrieved on: 
Saturday, September 16, 2023
ADM, DPP3, Research and development, Sepsis, Radboud University Medical Center, Septic, Organ dysfunction, Biomarker, Septic shock, Intensive care medicine, Plasma, Patient, Risk, Sir Ewan Forbes, 11th Baronet, Medicine, Mortality, Nursing care plan, Congress, Conference, Pharmaceutical industry

Adrenomed is preparing a confirmatory trial

Key Points: 
  • Adrenomed is preparing a confirmatory trial
    Enibarcimab is targeting loss of vascular integrity, a previously unaddressed pathophysiological mechanism [1]
    Adrenomed presenting on individualized precision medicine treatment at the World Sepsis Day Event, Berlin, September 12 [2]
    Hennigsdorf/Berlin (Germany), September 8, 2023 – Adrenomed AG, the vascular integrity company, today announced new findings on the biomarker-guided treatment of septic shock with enibarcimab.
  • New data analyses of the phase II clinical trial AdrenOSS-2 validate the precision medicine approach applied by Adrenomed in the development of its non-neutralizing antibody enibarcimab for the treatment of septic shock.
  • They underpin Adrenomed’s hypothesis that there is an interplay between baseline DPP3 levels and treatment effects of enibarcimab in patients with septic shock.
  • The AdrenOSS-2 trial has marked an important step forward in bringing our precision medicine approach to patients.

Adrenomed presents new findings on its precision medicine treatment for septic shock with enibarcimab during Weimar Sepsis Update

Retrieved on: 
Friday, September 8, 2023
ADM, DPP3, Research and development, Sepsis, Radboud University Medical Center, Septic, Organ dysfunction, Biomarker, Septic shock, Intensive care medicine, Plasma, Patient, Risk, Medicine, Mortality, Poster, Nursing care plan, Congress, Conference, Medical device, Pharmaceutical industry

Adrenomed is preparing a confirmatory trial

Key Points: 
  • Adrenomed is preparing a confirmatory trial
    Enibarcimab is targeting loss of vascular integrity, a previously unaddressed pathophysiological mechanism1
    Adrenomed presenting on individualized precision medicine treatment at the World Sepsis Day Event, Berlin, September 122
    HENNIGSDORF, Germany and BERLIN, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Adrenomed AG, the vascular integrity company, today announced new findings on the biomarker-guided treatment of septic shock with enibarcimab.
  • New data analyses of the phase II clinical trial AdrenOSS-2 validate the precision medicine approach applied by Adrenomed in the development of its non-neutralizing antibody enibarcimab for the treatment of septic shock.
  • They underpin Adrenomed’s hypothesis that there is an interplay between baseline DPP3 levels and treatment effects of enibarcimab in patients with septic shock.
  • The AdrenOSS-2 trial has marked an important step forward in bringing our precision medicine approach to patients.

Privacy Commissioner’s Office’s Response to the Incident relating to the Film To My Nineteen-Year-Old Self

Retrieved on: 
Monday, February 20, 2023
Student, Information privacy, DPP v Lennon, Incident, DPP3, Office of the Privacy Commissioner for Personal Data, Personal data, Privacy, Film, Collection, Disclosure, Privacy Commissioner

Date: 6 February 2023

Key Points: 
  • Date: 6 February 2023
    Privacy Commissioner’s Office’s Response to the Incident relating to the Film To My Nineteen-Year-Old Self
    The Office of the Privacy Commissioner for Personal Data (PCPD) noted the media reports on the personal data privacy issues relating to the film To My Nineteen-Year-Old Self.
  • In order to protect the personal data privacy of the relevant students (as data subjects), the PCPD has taken the initiative to contact the school concerned to ascertain the details of the incident.
  • Generally speaking, everyone’s personal data privacy should be protected and respected, regardless of age.
  • Any person who suspects that his or her personal data privacy has been infringed and can provide prima facie evidence (including details about misuse of the personal data) may lodge a complaint with the PCPD.

DGAP-News: Interdepartmental testing of the kidney function biomarker penKid in routine care at Heidelberg University Hospital and the Heidelberg Kidney Center

Retrieved on: 
Friday, August 26, 2022
Nexus, Mortality, Inflammation, CA, Renal replacement therapy, Hospital, Hennigsdorf, Disease, Clinic, Shock, Kinetics, PMID, AKI, Critical care, IMC, NZH, University Hospital Heidelberg, Standard of care, Sepsis, Immunoassay, Diagnosis, Prognosis, IVD, Dialysis, Dipeptidyl peptidase-4, CSO, Nephrology, Wang, High-dependency unit, Anesthesiology, Patient, Heart, CRRT, Kidney, Acute kidney injury, Biomarker, Jean-Louis Vincent, ICU, DPP3, Medical imaging, Medical device

Four units at the University Hospital Heidelberg and Heidelberg Kidney Center implement Proenkephalin (penKid) in a pilot biomarker-based treatment approach to diagnose AKI faster and monitor it more accurately across departments.

Key Points: 
  • Four units at the University Hospital Heidelberg and Heidelberg Kidney Center implement Proenkephalin (penKid) in a pilot biomarker-based treatment approach to diagnose AKI faster and monitor it more accurately across departments.
  • PenKid is a proposed biomarker for real-time kidney function that potentially closes on the gaps of the standard diagnostic procedures.
  • This includes the normal, the intermediate care (IMC), the nephrology, and the intensive care units (ICU) of both clinics in Heidelberg.
  • This routine use of penKid on a centralized level in the hospital drives innovation on multiple wards such as nephrology, ICU and IMC.

DGAP-News: Endothelial function biomarker bioactive Adrenomedullin (bio-ADM) enables triage of sepsis patients in the emergency department

Retrieved on: 
Monday, August 1, 2022
Nexus, CA, PCT, DPP3, Infection, Diagnosis, Pheochromocytoma, Critical Care (journal), Mortality, Physician, Septic shock, Lundberg, Biomarker, Sepsis, CSO, Risk, Triage, Pharmacology, News, IVD, Endothelial dysfunction, Disease, Teaching hospital, TSH, Patient, Jean-Louis Vincent, Professor, Pathology, Lund University, Association, High-dependency unit, N-terminal prohormone of brain natriuretic peptide, ICU, Critical care, Medical imaging, Medical device, Medicine, Hennigsdorf, Troponin

Unfortunately, sepsis is difficult to diagnose and treat because it has a high range of forms and intensities.

Key Points: 
  • Unfortunately, sepsis is difficult to diagnose and treat because it has a high range of forms and intensities.
  • In ED, it is still difficult to identify sepsis patients early, and assigning the correct further treatment is thus challenging.
  • Lundberg OHM, Rosenqvist M, Bronton K, Schulte J, Friberg H, Melander O (2022) Bioactive adrenomedullin in sepsis patients in the emergency department is associated with mortality, organ failure, and admission to intensive care.
  • SphingoTec's proprietary biomarker portfolio includes bioactive Adrenomedullin (bio-ADM), a biomarker for real-time assessment of endothelial function in conditions like sepsis, and Proenkephalin (penKid), a biomarker for real-time assessment of kidney function.

DGAP-News: SphingoTec appoints Jörg Menten as CEO to accelerate commercialization and global growth

Retrieved on: 
Thursday, June 30, 2022
Nexus, Incident management team, Diagnosis, Acquisition, Patient, Sepsis, CEO, N-terminal prohormone of brain natriuretic peptide, Precision medicine, Research, Adoption, PCT, Interventional radiology, Roche Diagnostics, Biomarker, DPP3, Growth, Liver cancer, Boston Scientific, CSO, CCO, CFO, MBA, Hennigsdorf, IVD, TSH, University, NYSE, University Hospital Mannheim, Point of care, Advisory board, CA, Advisory, The Advisory Board Company, Leadership, POC, IPO, Vanguard, Senior management, Management, Medical device, Critical care, Troponin

SphingoTec appoints Jrg Menten as Chief Executive Officer (CEO) as from July 1, 2022 to drive the commercialization and scale its diagnostic business.

Key Points: 
  • SphingoTec appoints Jrg Menten as Chief Executive Officer (CEO) as from July 1, 2022 to drive the commercialization and scale its diagnostic business.
  • Hennigsdorf/Berlin, Germany, June 30, 2021 Diagnostics company SphingoTec GmbH (SphingoTec) today announced that Jrg Menten was appointed CEO of SphingoTec effective of July 1, 2022.
  • Jrg Menten is a highly skilled senior executive with a long-standing track record of leadership positions in the global healthcare industry.
  • On behalf of the Advisory Board I welcome Jrg Menten in his new capacity as CEO of SphingoTec.

DGAP-News: Dipeptidyl peptidase 3 biomarker to drive precision medicine in COVID-19

Retrieved on: 
Tuesday, April 12, 2022
Life, Biomarker, Safety, Death, Clinical trial, Mortality, Patient, II, Heart, COVID-19, Gesellschaft mit beschränkter Haftung, Survival, Multiple organ dysfunction syndrome, Cardiac output, COVID 19, Teaching hospital, Precision medicine, Angiotensin, Hemodynamics, CEO, Jean-Louis Vincent, Medicine, DPP3, Critical care, Intensive Care Medicine (journal), Medication, Septic shock, Cardiogenic shock, DOI, Circulatory collapse, COVID, Consequential damages, Blood, Tracheal collapse, Organ dysfunction, Pharmaceutical industry, Hospital, Medical device, Vaccine, Latins (Italic tribe), Sepsis, Dipeptidyl peptidase

The study will be using two biomarkers, bioactive adrenomedullin (bio-ADM) and dipeptidyl peptidase 3 (DPP3), for patient stratification and inclusion criteria for the use of Adrecizumab (1).

Key Points: 
  • The study will be using two biomarkers, bioactive adrenomedullin (bio-ADM) and dipeptidyl peptidase 3 (DPP3), for patient stratification and inclusion criteria for the use of Adrecizumab (1).
  • This revolutionary approach could serve as a precision medicine strategy in patients with severe COVID 19 infection.
  • Both clinical pathways can be detected by specific biomarkers, bioactive Adrenomedullin (bio-ADM) for the loss of endothelial function and Dipeptidyl peptidase (DPP3) for the loss of heart function.
  • Med., DOI: doi.org/10.1111/joim.13220
    Magliocca, A.; Omland, T.; Latini, R. Dipeptidyl peptidase 3, a biomarker in cardiogenic shock and hopefully much more.

DGAP-News: PEI Regulatory Approval Received for Government Funded Clinical Trial Investigating Adrenomed's Adrecizumab in Treating Endothelial Barrier Dysfunction in Hospitalized COVID-19 Patients

Retrieved on: 
Tuesday, April 12, 2022
Risk, Drug development, LinkedIn, Manifest and latent functions and dysfunctions, Lung, Federal Ministry of Health (Germany), Trial of the century, Mortality, Paul Ehrlich Institute, PEI, Survival, BMBF, SOC, Precision medicine, Jean-Louis Vincent, DPP3, Sepsis, Intensive care medicine, Twitter, Septic shock, Adrenomedullin, COVID-19, Department, Education, INN, Organ dysfunction, Patient, Pharmaceutical industry, Medical device, Research

Additionally, the BMBF will support financially the manufacturing of GMP Phase III clinical trial material.

Key Points: 
  • Additionally, the BMBF will support financially the manufacturing of GMP Phase III clinical trial material.
  • Dysregulation of the endothelial barrier appears to be a common feature of COVID-19 patients and sepsis or septic shock patients.
  • In a novel precision medicine approach, patients with elevated adrenomedullin levels will be treated with Adrecizumab to restore and maintain the endothelial barrier and to avoid further organ dysfunction.
  • Adrecizumab has successfully completed a biomarker-guided, double-blinded, placebo-controlled, randomized, multicenter proof-of-concept Phase II trial with 301 patients suffering from septic shock.

DGAP-News: Biomarker-guided trial led by University Hospital Hamburg-Eppendorf (UKE) opens new avenues for personalized medicine in COVID-19

Retrieved on: 
Tuesday, April 12, 2022
Nexus, Biomarker, Safety, TSH, Diagnosis, IVD, Patient, Mortality, PCT, Gesellschaft mit beschränkter Haftung, Pathology, PD, Endotheliitis, Jean-Louis Vincent, N-terminal prohormone of brain natriuretic peptide, Medicine, Endothelial dysfunction, DPP3, Critical care, Sepsis, Intensive Care Medicine (journal), Intensive care medicine, Septic shock, CA, COVID-19, DOI, Trial of the century, Department, Decision-making, Pharmaceutical industry, Medical device, Medical imaging, Hospital, Lancet, Troponin

A multi-center study led by UKE is evaluating one of the first personalized approaches for moderate to severe COVID-19 patients.

Key Points: 
  • A multi-center study led by UKE is evaluating one of the first personalized approaches for moderate to severe COVID-19 patients.
  • The personalized approach will allow to distinguish between separate clinical pathways, requiring different treatment decisions.
  • This trial will implement the biomarker bioactive Adrenomedullin (bio-ADM) for early identification of endothelial dysfunction (1), which plays a central role in the pathophysiology of COVID-19 (2).
  • At the same time, patients with high Dipeptidyl peptidase 3 (DPP3) levels will not be included in the trial.